Skip to main content
. 2021 Jun 23;70(11):3337–3348. doi: 10.1007/s00262-021-02986-5

Fig. 2.

Fig. 2

Soluble and cellular biomarkers are significantly altered by mFOLFOX6 and pembrolizumab treatment. A heatmap displays soluble immune biomarkers that were assessed on this trial and how they were altered by treatment between baseline (C1D1) and cycle 1 day 15 (C1D15) (a). Significant changes in cellular biomarkers (b) are also displayed. Paired student’s t test used to compare C1D1 and C1D15 values. *P < 0.05. **P < 0.01, ***P < 0.001, ****P < 0.0001